-

SportsMed Physical Therapy Acquires Mountainside Wellness

GLEN ROCK, N.J.--(BUSINESS WIRE)--SportsMed Physical Therapy (“SportsMed” or the “Company”), a leading provider of physical therapy, chiropractic, acupuncture and occupational therapy services, today announced it has acquired the two clinics comprising Mountainside Wellness, another leading provider of physical therapy and chiropractic services in the central New Jersey (“NJ”) area.

The acquisition of the two clinics, located in Mountainside and Colonia, NJ, provides the Company with two additional locations in complimentary geographic areas to SportsMed’s existing 33 locations, and further supports the Company’s strategy to expand its footprint.

Dr. Peter Ponzini, Co-Chief Executive Officer, said of the acquisition, “We are incredibly excited to announce the acquisition of Mountainside Wellness. The team is thrilled to integrate these locations into the SportsMed platform as we continue to scale in the greater Tri-State area. We have a growing pipeline of opportunities and remain committed to expanding our platform and reach via incremental M&A.”

SportsMed is a portfolio company of Hildred Capital Management. Holland & Knight served as legal adviser to SportsMed on the transaction. Debt financing for the transaction was provided by Oxford Finance.

About SportsMed Physical Therapy

Founded in 2004, SportsMed is a physical therapy-focused physician practice management company, with 33 clinics that provide physical therapy, chiropractic, acupuncture, and occupational therapy services. SportsMed utilizes top of the line equipment and employs highly experienced professionals to provide quality care across the Company’s service lines. For more information, please visit www.spineandsportsmed.com.

About Hildred Capital Management

Hildred Capital Management is a New York-based private equity investment firm that pursues growth equity investments in lower middle market healthcare companies with leading products, technologies, and services. Hildred focuses on opportunities to create value from earnings growth, operational improvements, and multiple expansion in companies with revenues of $0 to $100 million. Areas with attractive fundamentals where Hildred may invest include the following healthcare subsectors: healthcare services, consumer products, information technology, medical devices, and pharmaceuticals; including the related industries that surround these healthcare subsectors. For more information, please visit www.hildred.com.

Contacts

Liz Simmons
Director of Brand and Business Development
SportsMed Physical Therapy
esimmons@SpineAndSportsMed.com

Hildred Capital Management


Release Versions

Contacts

Liz Simmons
Director of Brand and Business Development
SportsMed Physical Therapy
esimmons@SpineAndSportsMed.com

More News From Hildred Capital Management

Crown Laboratories Completes Acquisition of Revance Therapeutics

NEW YORK--(BUSINESS WIRE)--Yesterday, Crown Laboratories, Inc. ("Crown"), a Hildred Capital portfolio company and privately held, global innovative leader in the skincare industry, announced the closing of its acquisition of Revance Therapeutics, Inc. ("Revance") (NASDAQ: RVNC), a biotechnology company aimed at setting the new standard in healthcare with innovative aesthetic and therapeutic offerings. Jeff Bedard, Founder and Chief Executive Officer of Crown commented, “We are excited to offici...

Signet Healthcare Partners, Athyrium Capital Management, Hildred Capital and Pharmascience Inc. Announce Exit from Pharmaceutics International, Inc.

NEW YORK--(BUSINESS WIRE)--A consortium of investors led by Signet Healthcare Partners, Athyrium Capital Management, Hildred Capital and Pharmascience Inc. today announced they have exited their equity stake in Pharmaceutics International, Inc. (“Pii”), a contract development and manufacturing organization, and have closed on an undisclosed all-cash transaction to sell the company to Jabil Inc. (NYSE: JBL), a global leader in engineering, manufacturing, and supply chain solutions. Pii is a cont...

Hildred Capital Announces Oversubscribed Final Close of Hildred Equity Partners III with Capital Commitments in Excess of $800 Million

NEW YORK--(BUSINESS WIRE)--Hildred Capital Management, LLC ("Hildred"), a lower middle-market healthcare private equity firm, today announced the successful final closing of its third fund, Hildred Equity Partners III (the “Fund”). The Fund was significantly oversubscribed, exceeding its $600 million target and hitting its hard cap in seven months. With total capital commitments in excess of $800 million, the Fund represents more than double the size of its predecessor fund, Hildred Equity Part...
Back to Newsroom